INTRODUCTION {#sec1-1}
============

Iran has a population of 78 million and is the second most populated country in the Middle East and North Africa (MENA). About half of the population is under 35 years old.[@ref1] In the last two decades, the life expectancy at birth has increased by approximately 7 years and reached 74.4 (95% confidence interval \[CI\]: 72.2--76.6) years in 2010.[@ref2] Iran has experienced demographic and epidemiological transitions that could change the patterns of morbidity and mortality in the near and distant future. These changes involve the emergence of chronic noncommunicable diseases and health-related conditions of an aging population.[@ref3][@ref4] This transition has resulted in a shift in the allocation of health resources and health policy.

In the past 20 years, there has been a reduction in the age-standardized prevalence of blindness and moderate and severe vision impairment (MSVI) worldwide.[@ref5] While the blind population remained stable, the population with MSVI may have increased. This pattern could be related to population growth and the relative increase in the population of older adults.[@ref5] The most recent Rapid Assessment of Avoidable Blindness study among noninstitutional inhabitants aged ≥50 years in Tehran estimated the standardized prevalence rate of blindness, severe visual impairment (VI), and VI to be 1.33 (95% CI: 0.91--1.75), 1.39 (95% CI: 0.81--1.97), and 6.91 (95% CI: 5.96--7.86), respectively.[@ref6] These figures are slightly higher than the more recent (2010) age-standardized prevalence of blindness of 1.1% and moderate and severe VI of 4.5% in the North Africa and the Middle East, respectively.[@ref7]

Advocacy for the prevention of blindness relies on data the prevalence and burden of blindness and VI, the major avoidable causes, and the natural trends over time. Currently, there are no published data on the burden of blindness and VI in Iran. In the current study, we investigate and report disability-adjusted life-years (DALYs) lost due to four major eye diseases in Iran and compare changes in the burden from 1990 to 2010 based on gender and age using the Global Burden of Disease Study 2010 (GBD 2010) results.[@ref8]

GBD 2010 began in 2007 as a collaborative project with the Institute for Health Metrics and Evaluation (IHME) at the University of Washington as the coordinating center working with six other core collaborators including the University of Queensland, Harvard School of Public Health, the Johns Hopkins Bloomberg School of Public Health, the University of Tokyo, Imperial College London, and the World Health Organization. This study provides a new platform for assessing the world\'s biggest health challenges.[@ref9]

METHODS {#sec1-2}
=======

We report DALYs in Iran for eye diseases using the GBD 2010 outcomes.[@ref8] The GBD 2010 data includes DALYs, years lived with disability (YLDs), and years of life lost (YLLs) for each specific disease. Measurement of the GBDs using DALYs requires weights that quantify disabilities (or health losses) for all nonfatal consequences of diseases and injuries in terms of years lost.[@ref10] Judgment about health losses associated with eye diseases and injuries are elicited from the general public in diverse communities through a new, standardized approach.[@ref10]

In the GBD 2010 study, eye diseases are categorized under sense organ diseases that include cataract, refraction/accommodation (functional) disorders, macular degeneration, glaucoma, other vision loss, other hearing loss, and other sense organ diseases. In this study, we focus on the first four eye diseases. Due to their nonfatal nature, there are no YLLs attributed to eye diseases; hence, DALYs and YLDs have the same values. We report the rate of DALYs for 100,000 populations to adjust for the changes in the age distribution over years. We compare DALYs for each eye disease between 1990 and 2010 and among 20 age groups from early neonatal (EN) phase to 80 years of age and older and separately for males and females. The age groups are defined in [Table 1](#T1){ref-type="table"}.

###### 

The definition of age groups used in the study
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RESULTS {#sec1-3}
=======

[Table 2](#T2){ref-type="table"} presents absolute, as well as the percentage values of DALYs attributed to four eye diseases. It also provides global figures and those from the MENA region for comparison.

###### 

Total and eye diseases DALYs in Iran, the MENA region and the World in: 1990-2010[@ref10]
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Cataract {#sec2-1}
--------

In 1990, DALY attributed to cataract per 100,000 population of Iran ranged from 0 in EN to 1.97 (95% UI; 0.71, 4.01) for ages 20--24 years and 681.41 (95% UI; 497.04, 901.58) for age 80 years and older for both sexes. There was a steady increase in DALY attributed to cataract with age from EN to 80+ years and among males and females \[[Graph 1](#F1){ref-type="fig"}\] with the highest DALY of 631.07 (95% UI; 444.47, 883.29) among males aged 80 years and older and the highest DALY of 726.71 (95% UI; 507.95, 999.5) among females aged 80 years and older. In 2010, DALY attributed to cataract per 100,000 population ranged from 0 in EN to 0.93 (95% UI; 0.21, 1.96) for ages 20--24 years and 318.32 (95% UI; 231.84, 428.15) for age 80 years and older for both sexes. There was a steady increase in DALY attributed to cataract with age \[[Graph 1](#F1){ref-type="fig"}\] with the highest DALY of 300.17 (95% UI; 197.86, 434.02) among males aged 80 years and older and the highest DALY of 338.77 (95% UI; 217.94, 491.85) among females aged 80 years and older. The point-by-point comparison of DALY attributed to cataract showed a decrease for each specific age group from 1990 to 2010 for both sexes and in males and females \[[Graph 1](#F1){ref-type="fig"}\].

![Disability-adjusted life-years per 100,000 for cataract in different sex and years](MEAJO-23-89-g003){#F1}

Refraction/accommodation (functional) disorders {#sec2-2}
-----------------------------------------------

In 1990, the DALY attributed to functional disorders per 100,000 population of Iran ranged from 0.8 (95% UI; 0, 2.57) in EN to 17.82 (95% UI; 11.39, 25.66) for ages 10--14 years, 10.26 (95% UI; 6.17, 15.27) for ages 20--24 years, and 555.56 (95% UI; 410.7, 732.13) for 80 years and older for both genders. There was a steady increase in DALY attributed to refraction/accommodation (functional) disorders with age from EN to 10--14 years old and a slight decrease thereafter until the age of 20--24 years. The attributed DALY had a steady increase from ages 40 to 80+ years in both genders \[[Graph 2](#F2){ref-type="fig"} top row\] with the highest DALY of 505 (95% UI; 354.18, 695.23) among males aged 80 years and older and the highest DALY of 601.63 (95% UI; 430.15, 812.2) among females aged 80 years and older. In 2010, DALY attributed to refraction/accommodation (functional) disorders per 100,000 population ranged from 0.7 (95% UI; 0, 2.48) in EN to 16.45 (95% UI; 10.53, 24.49) for ages 10--14 years, 9.81 (95% UI; 6.06, 14.83) for ages 20--24 years, and 531.37 (95% UI; 393.2, 708.46) for ages 80 years and older for both genders. The DALY trend by age was similar to 1990 data with the highest DALY of 484.6 (95% UI; 345.81, 670.35) among males aged 80 years and older and the highest DALY of 584.09 (95% UI; 409.87, 797.63) among females aged 80 years and older. The point-by-point comparison of DALY attributed to refraction/accommodation (functional) disorders showed a slight decrease for each specific age group from 1990 to 2010 for both genders and among males and females. The change was larger in the older age groups compared to younger age groups \[[Graph 2](#F2){ref-type="fig"}\].

![Disability-adjusted life-years per 100,000 for refraction/accommodation disorders in different sex and years](MEAJO-23-89-g004){#F2}

Macular degeneration {#sec2-3}
--------------------

In 1990, DALY attributed to macular degeneration per 100,000 population of Iran ranged from 0 in EN to 2.36 (95% UI; 088, 4.29) for ages 45--49 years and 343.02 (95% UI; 241.49, 470.45) for age 80 years and older for both genders. There was a steady increase in DALY attributed to macular degeneration with age from EN to 80+ years in both genders and among males and females \[[Graph 3](#F3){ref-type="fig"} top row\] with the highest DALY of 269.73 (95% UI; 163.20, 410.33) among males aged 80 years and older, and the highest DALY of 409.81 (95% UI; 270.26, 589.98) among females aged 80 years and older. In 2010, DALY attributed to macular degeneration per 100,000 population ranged from 0 in EN to 4.35 (95% UI; 1.97, 7.79) for ages 45--49 years and 522.5 (95% UI; 379.16, 696.88) for age 80 years and older for both genders. There was a steady increase in DALY attributed to macular degeneration with age from EN phase to 80+ years in both genders and among males and females \[[Graph 3](#F3){ref-type="fig"} bottom row\] with the highest DALY of 447.61 (95% UI; 306.74, 645.45) among males aged 80 years and older, and the highest DALY of 606.92 (95% UI; 420.35, 849.74) among females aged 80 years and older. The point-by-point comparison of DALY attributed to macular degeneration showed an increase for each specific age group from 1990 to 2010 for both genders together and among males and females separately \[[Graph 3](#F3){ref-type="fig"}\].
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Glaucoma {#sec2-4}
--------

In 1990, DALY attributed to glaucoma per 100,000 population of Iran ranged from 0 in EN to 0.11 (95% UI; 0, 0.51) for ages 20--24 years and 116.52 (95% UI; 73.75, 172.68) for age 80 years and older for both genders. There was a steady increase in DALY attributed to glaucoma with age from EN to 80+ years in both sexes and among males and females \[[Graph 4](#F4){ref-type="fig"} top row\] with the highest DALY of 133.57 (95% UI; 74.05, 213.47) among males aged 80 years and older, and the highest DALY of 100.99 (95% UI; 58.34, 171.53) among females aged 80 years and older. In 2010, DALY attributed to glaucoma per 100,000 population ranged from 0 in EN to 0.19 (95% UI; 0, 0.69) for ages 20--24 years and 112.56 (95% UI; 73.69, 162.53) for age 80 years and older for both genders. There was a steady increase in DALY attributed to glaucoma with age from EN phase to 80+ years in both genders and among males and females \[[Graph 4](#F4){ref-type="fig"} bottom row\] with the highest DALY of 131.43 (95% UI; 77.31, 204.88) among males aged 80 years and older, and the highest DALY of 91.27 (95% UI; 53.93, 149.07) among females aged 80 years and older. The point-by-point comparison of DALY attributed to glaucoma showed a slight change for each specific age group from 1990 to 2010 for both genders and among males and females with a slight decrease in some age groups and slight increase in others \[[Graph 4](#F4){ref-type="fig"}\].

![Disability-adjusted life-years per 100,000 for glaucoma in different sex and years](MEAJO-23-89-g006){#F4}

DISCUSSION {#sec1-4}
==========

In 2010, noncommunicable diseases accounted for 70.42% (95% UI; 67.36, 73.08) and eye diseases accounted for 0.64% (95% UI; 0.9, 1.68) of national DALY in Iran.[@ref8] During the same time period, eye diseases accounted for 1.05% and 0.76% of national DALY in the MENA region and worldwide, respectively.[@ref11]

Among the four eye diseases studied, the burden of refraction/accommodation (functional) disorders has a higher rank in Iran followed by Cataract, Macular Degeneration, and Glaucoma, respectively. The ranking is the same globally and in the MENA region. There has been an increase from 1990 to 2010 in DALY attributed to eye diseases in Iran, globally, and in the MENA region with macular degeneration showing the highest increase. Cataract showed a decrease in attributed DALY from 1990 to 2010 in Iran. This pattern underscores the age-related nature of the blinding conditions and the epidemiologic transition in Iran. This is most evident in the case of macular degeneration.

The point-by-point decrease in DALY related to cataract \[[Graph 1](#F1){ref-type="fig"}\] and refraction/accommodation (functional) disorders \[[Graph 2](#F2){ref-type="fig"}\] is attributable to the current treatment options of these conditions and the popularity, as well as the effectiveness of cataract surgery. The availability of phacoemulsification for wider age groups and those with systemic comorbidities play an important role in the decreased DALY for cataract in Iran.[@ref12] In fact, theoretically cataract loses its chronic disease classification because surgical care is provided as soon as it is needed. Two opposing processes, namely, epidemiologic transition and access to the sight-restorative surgery play a role in the change in DALY attributed to cataract in Iran. This may explain the observation that changes in the cataract burden are comparatively lower than other blinding conditions.[@ref12]

It is important to note that the burden of existing diseases is not merely a reflection of the prevalence, natural course, and severity of a health condition. It also is a reflection of human intervention and effort in controlling that entity. Alternately, a higher burden alone in a specific area should not result in greater resource allocation for that issue as the value that is gained may be comparatively low. Hence, there must be a judicious allocation of resources.

An interesting finding related to refraction/accommodation (functional) disorders is the bimodal nature of the curve \[[Graph 2](#F2){ref-type="fig"}\], following the two broad categories of refractive errors in children and adolescents and in the middle age and older ages (presbyopia). Presbyopia affects the majority of the population over the age of 50 years[@ref13] and in the coming decades, its impact is expected to be further appreciated as near vision gains an ever-increasing functional value in the digital age. Another related development is that presbyopia is becoming a "surgical disease" in the coming decade.[@ref14]

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older individuals. The dramatic absolute and relative increase in the burden of macular degeneration best portrays the age-related nature of a condition that is largely untreatable. We expect that the proportion for AMD will continue to increase. This trend corresponds with other age-related health conditions such as Alzheimer\'s disease.[@ref15] This increase in Iran is lower than the MENA region\'s average and higher than the global average. In addition, macular degeneration ranks higher among all diseases in Iran compared to the global and the MENA averages.

The dramatic increase of the burden of glaucoma could be explained by improved diagnosis. Glaucoma has a long asymptomatic course (average 5--14 years[@ref16][@ref17]). The other feature of glaucoma as compared with cataract is that this condition is not curable, and the therapy is lifelong. Therefore, the burden is lifelong.

A rather unexpected finding is the lack of gender disparity. Commonly, in developing countries, there is a higher rate of affliction for females. It should be noted that the four major vision-impairing entities evaluated in this study are not known to be gender-related. In fact, there is some evidence supporting a relatively higher prevalence of glaucoma and cataract among females.[@ref18][@ref19] Alternately, the consistent higher burden of the aforementioned conditions in females in the older age groups denotes, the longer life expectancy and a greater proportion of females in those age groups.

Gender disparity in eye diseases and access to eye care services has been associated to poor visual outcomes.[@ref20] Several studies have reported the impact of economic inequality on health. The utilization of eye care services and the economic inequality might play a role in the burden of different eye conditions among age groups, between genders, among different socioeconomic groups, and in different geographical areas in the country. For example, the Shahroud eye cohort study, a population-based study in Northern Iran conducted in 2009, with 5190 respondents aged 40--64 years of age showed that 16.32% of participants had never used ophthalmic, or optometric services and 30.94% of these individuals had not done so over the past 5 years. Those with lower education, no valid insurance, lower economic status, and females seemed to have less access to eye care services.[@ref20]

The change in eye care services over the last two decades has played a role in the burden of eye diseases in Iran \[[Table 3](#T3){ref-type="table"}\]. There has been an increase in the number of ophthalmologists/optometrists in Iran over the last two decades. Additionally, there has been an increase in healthcare facilities and the percentage share of gross domestic product allocated to healthcare in Iran.

###### 

The comparative best guess profile on eye services in Iran
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This study has some limitations. GBD 2010 includes large amounts of data on health status risk factors, but they are hardly relevant to ophthalmic conditions; hence, we could report on these factors. The sources of data in GBD 2010 are heterogeneous; this limits the comparability of the findings. Some conditions such as congenital cataract (and broadly, childhood blindness) are not reflected in the accessible results despite representing a significant burden. Notably, some major disabling and blinding eye conditions are classified elsewhere, e.g., diabetic retinopathy, retinopathy of prematurity, HIV retinitis, ocular malignancies, optic neuropathies, autoimmune and allergic eye conditions, and cicatricial trachoma. Finally, a condition such as severe dry eye syndrome that is not included in the GBD cause list has consistently been reported to be associated with high disabilities comparable to heart failure.[@ref23]

In the GBD 2010 study, the attributed disability weight of blindness was reduced from 0.6 of 1999 to 0.2 and the burden estimates of 1990 were recalculated.[@ref5] This change will cause a massive depreciation in the ranking of the burden of VI in diseases. The implication is might be grave for eye care as it may result in excluding prevention of blindness from future public health policy initiatives. Other diseases such as HIV, mental health, and injuries have captured the attention of public health policy makers. The disability weights are drawn from global surveys, which might require further validation. Additionally, some individuals may not perceive the role of VI in mental health of the disabled person, as well as of that of the caregiver; the link between fall and fractures with VI may not be realized in the first place. Some experts have recommended a utility assessment[@ref23] approach and objective disability quantifications.[@ref24]

We believe that the burden of diseases paradigm is not optimized for presenting the impact of eye health and VI, as many of the blinding entities are listed elsewhere and many other important (nonblinding) eye conditions are not included at all. The attributed disability weight of 0.2 for blindness is too low.

CONCLUSION {#sec1-5}
==========

Epidemiologic transition is clearly reflected in the major ophthalmic and blinding diseases in Iran. The burden of macular degeneration burden is increasing, followed by glaucoma. Presbyopia manifests its impact after individuals are middle aged. However, the burden of cataract is increasing slowly, which is likely attributable to improved surgical care. Efforts are required to pool and project the burden of ophthalmic diseases by adopting a more realistic disability weight of blindness.
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